Main characteristics:
International and chemical name: acetylsalicylic acid
Main physical-chemical properties: tablets of white colour, with flat surface and facet.
Content: acetylsalicylic acid - 0,1 g
Excipients: microcrystallic croscarmellose, colloidal dioxide silicon (aerosil), srtearic acid - enough to achieve tablet with the mass - 0,112 g
Form of output: Tablets of white colour, containing 0,1 g of acetylsalicylic acid.
Pharmacological group: antiagregant remedy.
Pharmacological properties: Aspecard has anti-thrombotic effect, stipulated by ability of acetylsalicylic acid to inhibit cyclooxygenaze of thrombocytes, inhibiting in thrombocytes synthesis of thromboxane A2 and decreasing agregant activity of thrombocytes.
Aspecard also has febrifugal, anti-inflammatory and anaesthetic activity, characteristic of acetylsalicylic acid.
Indications for administration:
Aspecard is used as antiagregant remedy under non-stable stenocardia, acute myocardium infarct, thromboses and embolisms after operations on vessels, transferring disorders of brain blood circulation and ishemic insults, thromboses of coronary artery.
Way of administration and dosage: The medicine is administrated 1 tablet 1 time per day after meal. The dose can be increased up to 2-3 tablets per day for the prophylaxis of repeated myocardium infarct. The medicine is intended for the prolonged administration (from 1 - 2 months to 2 years), duration of which is determined individually.
Side effects: Under the administration of the medicine in separate patients nausea, vomiting, diarrhea, unpleasant feelings in the upper part of stomach, erosive and ulcerous breaches of stomach, breach of liver and kidneys, allergic reactions (skin rash, itch, nettle-rash) are possible.
Contraindications: Decreased coagulation of blood, hemophilia, erosive and ulcerous breaches of alimentary canal in the phase of exacerbation, 3rd term of pregnancy, increased sensitivity to salicylates.
Interaction with other drugs: acetylsalicylic acid strengthens the action of anticoagulants, non-steroid anti-inflammatory remedies, metotrexate. Under the combined administration glucocorticoides and ethanol, probability of ulcerogene action of the medicine increases, risk of beginning of gastro-intestinal hemorrhage rises. The medicinal product weakens the action of diuretics and uricosuric remedies.
Peculiarities of administration: It should be very carefully administrated to the patients with high sensitivity to non- steroid anti-inflammatory medicines, bronchial asthma, erosive-ulcerous and inflammatory problems of alimentary canal, malfunction of kidneys. When carrying out a prolonged therapy or taking big doses of the medicinal product, constant blood coagulation control and hemoglobin level control are required.
Storage conditions and shelf-life: Keep in dry, cool place, away from direct sunlight.
Conditions of output: Without prescription.
Packing: 6, 12 or 24 tablets in contour cell package, made of polyvinylchloride film and aluminium printed varnished foil. 30, 50 or 300 tablets into polymer container. Container or 10 contour cell packages together with instruction for usage are placed into cardboard package for consumer packing.
Manufacturer. SC "Concern Stirol"
Address: Gorlovskoy divizii str. 10, Gorlovka, Donetsk reg., Ukraine, 84610.
Adress in Internet: http://pharm.stirol.net
E-mail: support
